Human Immunology Biosciences Funding: $120M Raised, Series B
Human Immunology Biosciences is based in United States. It has raised $120M in total funding. Latest round: Series B.
Human Immunology Biosciences funding overview
Human Immunology Biosciences is based in United States. Human Immunology Biosciences has raised $120M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in January 2024. The round record for Human Immunology Biosciences runs through 2024; nothing later has been disclosed. Investors on record include ARCH Venture Partners, Monograph Capital. 2 distinct backers are named across the disclosed rounds.
Human Immunology Biosciences at a glance
Total raised
$120M
Latest round
Series B
Latest round date
January 2024
Headquarters
United States
Notable investors
ARCH Venture Partners, Monograph Capital
Frequently asked about Human Immunology Biosciences funding
How much has Human Immunology Biosciences raised?
Human Immunology Biosciences has raised $120M in total disclosed funding across the rounds on record.
Who has invested in Human Immunology Biosciences?
ARCH Venture Partners, Monograph Capital are named among the investors backing Human Immunology Biosciences.
What was the latest Human Immunology Biosciences funding round?
The most recent disclosed round is a Series B, announced in January 2024.
Where is Human Immunology Biosciences based?
Human Immunology Biosciences is based in United States.
When did Human Immunology Biosciences last raise?
The last disclosed Human Immunology Biosciences round closed in January 2024 at Series B.
Totals shown for Human Immunology Biosciences aggregate every disclosed round on file. To see how that compares, browse the companies in United States and the investors behind them below.
Companies related to Human Immunology Biosciences (36)
